Company Encyclopedia
View More
name
JXR
01951.HK
Jinxin Fertility Group Limited, an investment holding company, provides assisted reproductive services (ARS) in China and the United States. It offers two treatment solutions, including artificial insemination that is performed with either husband’s sperm or a donor sperm; and IVF technology, whereby fertilization is achieved through conventional in vitro fertilization and embryo transfer or IVF with intracytoplasmic sperm injection. The company also provides related services, such as nutrition guidance, Chinese medicine treatment, and psychological counseling to support the ARS. In addition, the company offers management services; obstetrics, gynecology, urology, internal medicine, and pediatrics medical services; ambulatory surgery center facilities services; and ancillary medical services.
52.63 B
01951.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
Health Care ServicesIndustry
Industry Ranking18/28
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-9.78%D
    • Profit Margin-35.63%E
    • Gross Margin30.38%C
  • Growth ScoreD
    • Revenue YoY-8.22%D
    • Net Profit YoY-404.96%E
    • Total Assets YoY-3.90%D
    • Net Assets YoY-8.20%D
  • Cash ScoreD
    • Cash Flow Margin-280.66%D
    • OCF YoY-8.22%D
  • Operating ScoreD
    • Turnover0.18D
  • Debt ScoreB
    • Gearing Ratio33.95%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Morning Trend | JXR's capital withdrawal, is defensive sentiment intensifying under weak fluctuations?

    JXR (1951.HK) has recently experienced continuous capital outflow, and the MACD death cross structure indicates a bearish short-term trend. The stock price has been declining and is currently near the previous low support zone. Active buying is weak, and existing funds are mostly reducing positions to manage risks. The intraday price fluctuations have narrowed, and the main force's short-term participation has decreased, with defensive sentiment significantly rising. If there is an influx of incremental capital today, combined with a market sentiment recovery, there may be a tentative rebound; otherwise, the weak oscillation will continue. From a fundamental perspective, short-term growth expectations are average, and the unstable external market environment makes it difficult for capital to perform. Short-term operations should be defensive, focusing on technical rebound signals or market anomalies, and avoid blindly increasing positions against the trend. Considering both fundamentals and technical patterns, it is recommended to remain patient and wait for clearer opportunities

    Technical Forecast·
    HK
    01951
    +2.80%
    Technical Forecast·
    HK
    01951
    +2.80%

    JXR: Zhong Manna has been appointed as the company secretary and authorized representative

    JXR announced that, effective October 31, 2025, Ms. Zhai Yangyang will resign as the co-company secretary of the company, and Ms. Wu Xiuwai will resign as the co-company secretary and authorized representative. Zhai Yangyang is resigning for personal career development, while Wu Xiuwai is resigning due to other work arrangements. Ms. Zhong Manna will be appointed as the company secretary and authorized representative effective October 31, 2025

    Zhitong·
    HK
    01951
    +2.80%
    Zhitong·
    HK
    01951
    +2.80%

    In the first three quarters, JXR made significant progress in the number of egg retrieval cycles in vitro fertilization (IVF)

    In the nine months ending September 30, 2025, JXR significantly increased the number of IVF egg retrieval cycles, with the overall decline narrowing from -8.3% to -5.2%. The decline at the Chengdu hospital decreased from -6.1% to -1.9%, while the Shenzhen hospital's improvement was slow due to relocation plans. The decline in the number of IVF cycles in the U.S. market was in line with expectations due to the postponement of legislation. The company remains confident in the industry's prospects and future growth, benefiting from industry fundamentals, policy support, and continuous efforts

    Zhitong·
    HK
    01951
    +2.80%
    Zhitong·
    HK
    01951
    +2.80%

    Executive Director Dong Yang increased his holdings in JXR by 500,000 shares at a price of HKD 2.56 per share

    According to the latest information from the Hong Kong Stock Exchange, on October 15th, Executive Director Dong Yang increased his holdings in JXR by 500,000 shares at a price of HKD 2.56 per share, totaling HKD 1.28 million. After the increase, the latest number of shares held is approximately 13.373 million, with a latest holding ratio of 0.48%

    Zhitong·
    HK
    01951
    +2.80%
    Zhitong·
    HK
    01951
    +2.80%

    JXR recommends adopting the 2025 share plan

    JXR's board of directors recommends adopting the 2025 share plan, which requires shareholder approval. The plan aims to align the long-term interests of directors and key employees with the company's interests, incentivizing them to drive company growth. The plan includes granting 137,235,000 stock options to management, as well as granting 2.4 million stock options and 1.2 million restricted shares to non-executive grantees

    Zhitong·
    HK
    01951
    +2.80%
    Zhitong·
    HK
    01951
    +2.80%
    © 2025 Longbridge｜Disclaimer